Dennis Gillings, London-born professor at the University of North Carolina (UNC), signs his first consulting contract. His team of part-time staff working in a trailer on the UNC campus provides statistical and data management consulting for pharmaceutical customers. Quintiles is formally incorporated in North Carolina, co-founded by Gillings and Gary Koch, who remains as a professor at the University of North Carolina.
Quintiles begins its global expansion, opening its United Kingdom operations to serve customers in Europe. The office moves from London to Reading in 1989 and to Bracknell in 1994. In 2011, Quintiles moves back to Reading, opening its new European headquarters in Green Park.
Quintiles Laboratories Ltd. opens in Atlanta, expanding from one small room offering safety testing to a global network with a full-service offering, including biomarkers to esoteric evaluations. Today, it is a one-source solution for lab testing across the development spectrum, anywhere in the world.
Quintiles establishes operations in Asia, opening in Tokyo to extend services to Japanese customers. Today, Quintiles Asia spans the continent, opening in about 20 cities, from Singapore to Seoul, Beijing to Bangalore, Tokyo to Taipei.
Quintiles goes public, completing an initial public offering of Quintiles stock.
Quintiles establishes its Consulting practice with the acquisition of a globally recognized healthcare policy research and management consulting company. Today, Quintiles helps customers move from insight to execution. Our consulting practices are Product Development & Commercialization, Market Access, Regulatory & Quality, Market Intelligence, Late Phase, and IT Strategy & Implementation.
Quintiles combines with Innovex Ltd., a UK-based contract pharmaceutical company specializing in sales and marketing services for major pharma companies. The addition of Innovex makes Quintiles the world's largest full-service biopharmaceutical services company and enables Quintiles to provide services across the product lifecycle.
Growth through Partnering
Quintiles acquires Hoechst Marion Roussel's drug development facility in Kansas City and employs about 500 of its staff. In addition, Quintiles partners with HMR over five years for support of ongoing HMR projects. The group expands and in 2007, Quintiles moves to a new facility in Overland Park with a 150-bed Phase I Unit, and room for up to 200 more employees.
Capital and Commercial Combined
Quintiles signs landmark partnership agreement with Eli Lilly and Company to commercialize Cymbalta®. Quintiles makes an initial $110 million investment and provides a dedicated primary care team comprising some 500 representatives, 50+ managers, four regional trainers and a national trainer based in-house. Cymbalta® exceeds all sales forecasts, topping $3 billion by year three.
Quintiles becomes a private company led by founder and Chairman Dennis Gillings, CBE, PhD.
Quintiles moves into new world headquarters, Quintiles Plaza, in Durham, NC. Quintiles' expanded Asia-Pacific headquarters opens in November 2009 and its new European headquarters is inaugurated in the U.K. in October 2011.
Real World Powerhouse
With late phase and observational research becoming increasingly important to multiple healthcare stakeholders, Quintiles acquires Outcome Sciences, positioning Quintiles as the industry powerhouse in late phase and real world research.
Quintiles returns to the public markets again with its listing on the New York Stock Exchange.
Named to the Fortune 500 list of largest U.S. companies
Quintiles is named to the list of Fortune 500 list of the largest U.S. companies ranked by revenue in the magazine's June 16 issue.